You are here

  • Home
  • Archive
  • Volume 9, Issue 1
  • Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma

Article metrics

Article menu

Download PDFPDF

Clinical/translational cancer immunotherapy
Original research
Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma

 

Online download statistics by month:

Online download statistics by month: January 2021 to August 2024

AbstractFullPdf
Jan 2021338338104
Feb 2021355356156
Mar 2021547548120
Apr 202120320457
May 202117117255
Jun 202122122151
Jul 202113013034
Aug 202115515552
Sep 202111611635
Oct 202110510544
Nov 202111511557
Dec 202112312345
Jan 202210010147
Feb 2022575827
Mar 2022404034
Apr 2022363727
May 2022555641
Jun 2022535535
Jul 2022687029
Aug 2022818324
Sep 2022787928
Oct 2022878734
Nov 2022656723
Dec 2022626222
Jan 2023798114
Feb 2023818114
Mar 2023838522
Apr 2023707026
May 2023727228
Jun 2023787825
Jul 2023767620
Aug 2023606013
Sep 2023505012
Oct 2023646518
Nov 2023787817
Dec 2023747417
Jan 2024363722
Feb 2024545421
Mar 2024777721
Apr 2024939330
May 2024606024
Jun 2024646323
Jul 2024889228
Aug 2024585614
Total475647801590